Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

Post time 5 day(s) ago

journal：Gastroenterology

Authors：Virginia C. Clark; Charlie Strange; Pavel Strnad; Antonio J. Sanchez; Paul Kwo; Vitor Magno Pereira; Bart van Hoek; Igor Barjaktarevic; Angelo Guido Corsico; Monica Pons; Monica Goldklang; Meagan Gray; Brooks Kuhn; Hugo E. Vargas; John M. Vierling; Raj Vuppalanchi; Mark Brantly; Naomi Kappe; Ting Chang; Thomas Schluep; Rong Zhou; James Hamilton; Javier San Martin; Rohit Loomba

Published date：2024-7-

DOI：10.1053/j.gastro.2024.06.028

PDF link：https://www.sciencedirect.com/sc ... 016508524051813/pdf

Article link：http://dx.doi.org/10.1053/j.gastro.2024.06.028

Article Source：Elsevier BV。

Remark：

Post time 5 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA) Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)